Camp, William R. The prognostic assay was constructed using a genetic algorithm and validated on an independent cohort of 246 serial primary melanomas collected from 1997 to 2004. == Results == Multiple iterations of the genetic algorithm yielded a consistent five-marker solution. A favorable prognosis was predicted by ATF2 ln(non-nuclear/nuclear AQUA score ratio) of more than 0.052, p21WAF1nuclear compartment AQUA score of more than 12.98, p16INK4Aln(non-nuclear/nuclear AQUA score ratio) of 0.083, -catenin total AQUA score of more than 38.68, and fibronectin total AQUA score of 57.93. Primary tumors that met at least four of these five NP conditions were considered a low-risk group, and those that met three or fewer conditions formed a high-risk group (log-rankP< .0001). Multivariable proportional hazards analysis adjusting for clinicopathologic parameters shows that the high-risk group has significantly reduced survival on SB1317 (TG02) both the discovery (hazard ratio = 2.84; 95% CI, 1.46 to 5.49;P= .002) and validation (hazard ratio = 2.72; 95% CI, 1.12 to 6.58;P= .027) cohorts. == Conclusion == This multimarker prognostic assay, an independent determinant of melanoma survival, might be beneficial in improving the selection of stage II patients for adjuvant therapy. == INTRODUCTION == Adjuvant therapy is the standard of care for many low-stage cancers that can be completely resected with tumor-free margins. However, for some other cancers, the lack of effective and safe adjuvant therapy leads to an excess of mortality directly related to the development of metastatic disease in patients assumed to have undergone a complete resection of their malignancy. One important example is usually cutaneous malignant melanoma, the sixth most common cancer in the United States.1Although more than 80% of new cases are still localized to the skin1where a wide local excision should be curative in the setting of a negative sentinel lymph node biopsy, the unfavorable risk-to-benefit ratio of available adjuvant regimens advocates caution when administering such agents to individuals with stage I to IIA and even stage IIB or SB1317 (TG02) IIC disease, where high-dose interferon alfa-2b is currently approved by the US Food and Drug Administration in the adjuvant setting.2Consequently, 20% of these patients will develop metastases and die of their disease within 10 years, with more than 30% 10-year mortality among patients with T3 and T4 tumors.3Development of a prognostic tool that could selectively triage the subset of stage II patients at high risk of recurrence for adjuvant therapy could potentially lower the burden of untreatable metastatic cancer and enable us to selectively treat those patients who are more SB1317 (TG02) likely to develop distant metastatic disease. Nine clinicopathologic prognostic markers have been identified and incorporated into clinically validated outcome risk stratification models.3,4However, these do not account for all of the observed variability associated with melanoma-related survival. Immunohistochemistry (IHC) is usually a widely accepted and well-documented method for characterizing patterns of protein expression in formalin-fixed, paraffin-embedded samples while preserving tissue and cellular architecture.5Although no IHC marker has become standard of care, new work may suggest the inclusion of Ki-67.6Our recent systematic review of melanoma IHC data shows that individual contributions of IHC markers to overall prognosis are of narrow statistical significance and thus unlikely SB1317 (TG02) to demonstrate broad clinical utility7or see wide adoption. Here, we describe the generation of an independently significant, multimarker prognostic model for melanoma using genetic algorithms on a subset of 38 candidate proteins assessed on a cohort of 192 primary melanomas. Our model shows two prognostic groups (low risk and high risk), created from five markers, that were successfully validated as significant impartial prognostic factors in a second cohort of 246 primary melanomas. These data demonstrate the potential for multimarker assays in improving melanoma prognostic assessment and warrant a prospective, randomized, controlled melanoma prognostic study. This test could be a valuable tool to help determine which sentinel nodenegative stage II melanoma patients should seek adjuvant therapy or other aggressive management strategies. == METHODS == == Patients and Tumor Samples == Seven hundred thirty-seven tumor samples from three nonoverlapping series of patients with cutaneous melanoma were analyzed for protein expression. The Yale Melanoma Discovery Cohort consisted of 192 white patients who underwent resection of a primary invasive cutaneous melanoma at Yale-New Haven Hospital during 1959 to 1994 for whom the surgical specimen was not exhausted during diagnosis and for which follow-up information is usually available. The Yale Melanoma Validation Cohort included 246 patients with serial Clark level III to V cutaneous melanoma who underwent sentinel lymph node biopsy by a single surgeon during 1997 to 2004.8The Yale Metastatic Series includes 299 unique subcutaneous metastases, lymph node metastases, or visceral metastases occurring in patients previously diagnosed with cutaneous melanoma and surgically removed at Yale-New Haven Hospital during 1959 to 1994 (n = 198) or during 1995 to 2002 (n = 101). For the primary melanomas, clinical data describing patient demographics, date of diagnosis, clinical course, and follow-up through August 1,.